Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease

Thomas, Isac C.; Glassner-Kolmin, Cherylanne; Gomberg‐Maitland, Mardi

doi:10.1016/j.ijcard.2013.07.072

Cited by 33 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…42 Both long-term bosentan and sildenafil have improved symptoms and exercise capacity over time, 26,34,42,51 whereas the long-term effect of prostanoids has been rarely examined. 35,38 …”

Section: A C C E P T E Dmentioning

confidence: 99%

Advanced Therapy in Eisenmenger Syndrome

Hjortshøj

Jensen²,

Søndergaard³

2017

Cardiology in Review

View full text Add to dashboard Cite

Treatment options for patients with the Eisenmenger syndrome have until recently been scarce, but new knowledge in the field of pulmonary arterial hypertension has expanded the therapeutic possibilities for these patients. Advanced therapy with pulmonary vasodilators has become part of the standard treatment, offering long-term benefits on exercise capacity, clinical symptoms, and possibly survival. However, there are currently only few studies to guide the use of advanced therapies in this population, and important questions such as indications for initiation or escalation of advanced therapy and valid effect parameters and treatment goals remain unanswered. This review covers the pharmacology, therapeutic options, risk stratification, and treatment strategy of pulmonary arterial hypertension-specific drugs in patients with Eisenmenger syndrome.

show abstract

“…42 Both long-term bosentan and sildenafil have improved symptoms and exercise capacity over time, 26,34,42,51 whereas the long-term effect of prostanoids has been rarely examined. 35,38 …”

Section: A C C E P T E Dmentioning

confidence: 99%

Advanced Therapy in Eisenmenger Syndrome

Hjortshøj

Jensen²,

Søndergaard³

2017

Cardiology in Review

View full text Add to dashboard Cite

show abstract

“…With regards to patients on intravenous prostanoids, full anticoagulation should be considered in view of the risk of line-related thrombosis and paradoxic emboli. This, of course, has to be balanced against the risk of bleeding, possibly exacerbated by the antithrombotic properties of prostanoid therapy [22]. B.…”

Section: A Eisenmenger Syndromementioning

confidence: 99%

“…Intravenous epoprostenol is, by many experts, felt to be the strongest available PAH-therapy [22]. Even more so than inhaled iloprost, it requires a high level of commitment by the patient and requires strategic planning to accommodate into a patient's life.…”

Section: Managing Therapies Including Inhaled and Intravenous Prostamentioning

confidence: 99%

The spectrum of pulmonary arterial hypertension in adults with congenital heart disease: management from a physician and nurse specialist perspective

Dimopoulos

Harries

Parfitt

2017

J Congenit Heart Dis

View full text Add to dashboard Cite

Congenital heart disease (CHD) is one of the most common causes of pulmonary arterial hypertension (PAH), with a prevalence nearing that of idiopathic PAH in registries. Despite similarities in pulmonary vascular pathology, PAH-CHD differs from idiopathic PAH and other types of PAH. In fact, PAH-CHD is a term that includes a wide spectrum of conditions and pathophysiologies, ranging from Eisenmenger syndrome to milder forms of PAH with systemic-topulmonary shunts, to those with previously repaired defects. Significant expertise in both CHD and PAH is required to manage these patients. We provide an overview of the modern management of the wide spectrum of PAH-CHD in adults, both from a physician and clinical nurse specialist perspective.

show abstract

“…The response to corticosteroid treatment was evaluated in 35 See also Chapter 47. Prostaglandin and prostaglandin therapy is associated with a variety of indications including pulmonary arterial hypertension, glaucoma, and obstetrical diseases.…”

Section: Pharmacogenomicsmentioning

confidence: 99%

Corticotrophins, Corticosteroids, and Prostaglandins

Mody¹

2015

Side Effects of Drugs Annual

View full text Add to dashboard Cite

Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease

Cited by 33 publications

References 16 publications

Advanced Therapy in Eisenmenger Syndrome

Advanced Therapy in Eisenmenger Syndrome

The spectrum of pulmonary arterial hypertension in adults with congenital heart disease: management from a physician and nurse specialist perspective

Corticotrophins, Corticosteroids, and Prostaglandins

Contact Info

Product

Resources

About